Form 8-K - Current report:
SEC Accession No. 0000950170-24-090761
Filing Date
2024-08-05
Accepted
2024-08-05 16:15:00
Documents
13
Period of Report
2024-08-05
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tern-20240805.htm   iXBRL 8-K 42399
2 EX-99.1 tern-ex99_1.htm EX-99.1 117627
3 GRAPHIC img52906712_0.jpg GRAPHIC 6619
  Complete submission text file 0000950170-24-090761.txt   301010

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tern-20240805.xsd EX-101.SCH 26982
15 EXTRACTED XBRL INSTANCE DOCUMENT tern-20240805_htm.xml XML 5119
Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Filer) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39926 | Film No.: 241174932
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)